Durvalumab and Oleclumab in Resectable PDAC
This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.
Pancreatic Ductal Adenocarcinoma
DRUG: Durvalumab|DRUG: Oleclumab
Percent change in CD8+ cell infiltration, Baseline biopsy to surgical resection (35 days)
Percent change in CD3 cell population in tumour tissue, Baseline biopsy to surgical resection (35 days)|Percent change in CD3 cell population in blood, Baseline biopsy to surgical resection (35 days)|Percent change in CD45RA cell population in tumour tissue, Baseline biopsy to surgical resection (35 days)|Percent change in CD45RA cell population in blood, Baseline biopsy to surgical resection (35 days)|Percent change in RO T cell population in tumour tissue, Baseline biopsy to surgical resection (35 days)|Percent change in RO T cell population in blood, Baseline biopsy to surgical resection (35 days)|Percent change in M1 vs M2 macrophage population in tumour tissue, Baseline biopsy to surgical resection (35 days)|Percent change in M1 vs M2 macrophage population in blood, Baseline biopsy to surgical resection (35 days)
This is a multi-site Canadian, window of opportunity study to evaluate the immune activity of durvalumab and oleclumab in resectable pancreatic ductal adenocarcinoma (PDAC) when given prior to surgery.